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Research Article
Divergent androgen regulation of unfolded protein
response pathways drives prostate cancer
Xia Sheng1,‡, Yke Jildouw Arnoldussen1,†,‡, Margrethe Storm1,‡, Martina Tesikova1, Hatice Zeynep
Nenseth1, Sen Zhao1, Ladan Fazli2, Paul Rennie2, Bjørn Risberg3,4, Håkon Wæhre3,5,6, Håvard
Danielsen3,6,7, Ian G Mills8,9,10, Yang Jin1, Gökhan Hotamisligil11 & Fahri Saatcioglu1,3,*
Abstract
The unfolded protein response (UPR) is a homeostatic mechanism
to maintain endoplasmic reticulum (ER) function. The UPR is acti-
vated by various physiological conditions as well as in disease
states, such as cancer. As androgens regulate secretion and devel-
opment of the normal prostate and drive prostate cancer (PCa)
growth, they may affect UPR pathways. Here, we show that the
canonical UPR pathways are directly and divergently regulated by
androgens in PCa cells, through the androgen receptor (AR), which
is critical for PCa survival. AR bound to gene regulatory sites and
activated the IRE1a branch, but simultaneously inhibited PERK
signaling. Inhibition of the IRE1a arm profoundly reduced PCa cell
growth in vitro as well as tumor formation in preclinical models of
PCa in vivo. Consistently, AR and UPR gene expression were cor-
related in human PCa, and spliced XBP-1 expression was signifi-
cantly upregulated in cancer compared with normal prostate.
These data establish a genetic switch orchestrated by AR that
divergently regulates the UPR pathways and suggest that targeting
IRE1a signaling may have therapeutic utility in PCa.
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Introduction
The endoplasmic reticulum (ER) is an essential organelle which
regulates protein folding and secretion and impacts key functions in
the cell, such as lipid biosynthesis, and calcium homeostasis (Hetz,
2012). Different physiological and pathological conditions interfere
with the protein folding capacity of the ER, which leads to the accu-
mulation of unfolded or misfolded proteins, named ER stress (for a
review, see Tabas & Ron, 2011). In an attempt to cope with the
stress, several intracellular signal transduction pathways, collec-
tively termed the unfolded protein response (UPR), are activated.
The UPR signaling aims to increase the protein folding capacity in
the ER lumen, thus decreasing the unfolded protein load on the cell.
If the UPR is unsuccessful, however, apoptotic pathways are acti-
vated and cell death results.
The UPR is mediated by at least three well-conserved stress
sensors that are ER-localized transmembrane receptors: pancreatic
ER kinase-like ER kinase (PERK), activating transcription factor 6
(ATF6), and inositol-requiring kinase 1 (IRE1) (Tabas & Ron, 2011).
In the canonical model, in unstressed cells, these proteins are held
in an inactive state by protein chaperones, which inhibit their activ-
ity. Upon accumulation of unfolded or misfolded proteins, chaper-
ones dissociate from the transmembrane receptors and bind to the
unfolded proteins in the lumen of the ER allowing IRE1a and PERK
oligomerization in the ER membrane, and translocation of ATF6a to
the Golgi where it is cleaved into an active transcription factor. This
then leads to specific gene expression and signaling which in turn
orchestrates adaptation to ER stress.
Endoplasmic reticulum stress has been linked to many chronic
diseases, such as diabetes, neurodegeneration, various cancers, and
proinflammatory conditions (for reviews, see Hotamisligil, 2010;
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Clarke et al, 2014). In cancer, a wide range of cytotoxic conditions
such as hypoxia, pH changes, and nutrient deprivation trigger the
activation of the UPR to help the cancer cells to cope with the stress.
Thus, the ER stress response in this setting could be a cytoprotective
response with an important role in tumor growth, especially in
tumors arising from active secretory cells, such as the case in
multiple myeloma (for a review, see Tsai & Weissman, 2010). For
example, the IRE1a-X-box-binding protein 1 (XBP-1) pathway has
been shown to promote tumor growth in xenograft models (Romero-
Ramirez et al, 2004) and loss of XBP-1 sensitized cells to death from
oxidative stress (Liu et al, 2009). Transgenic mice studies have
shown that XBP-1 splicing occurs during primary tumor growth in a
number of breast cancer models (Spiotto et al, 2010). However,
under certain conditions, activation of the IRE1a or PERK pathways
may lead to apoptosis, for example by activating c-Jun N-terminal
kinase (JNK), and thereby inhibiting tumor growth (for a review,
see Clarke et al, 2014). Furthermore, UPR can impact autophagy
and mitophagy, two processes that can impart cancer cells survival
benefit (Kroemer et al, 2010; Maes & Agostinis, 2014). Thus, the
role of UPR in cancer cells is paradoxical: it is involved in the adap-
tive response of tumor cells, but also can initiate apoptotic cell death
(for a review, see Liu & Ye, 2011; Vandewynckel et al, 2013; Clarke
et al, 2014).
There is limited information on ER stress and UPR pathways in
PCa cells to date. Global gene expression profiling experiments in
androgen-treated PCa cells have shown changes in the expression of
some ER stress-associated genes, such as N-myc downstream-
regulated gene 1 protein (NDRG1), protein disulfide isomerase-related
protein (PDIR), homocysteine-responsive ER-resident ubiquitin-like
domain member 1 protein (HERPUD1), and oxygen-regulated
protein 150 (ORP150) (Segawa et al, 2002). In tumor models, gene
expression profiling indicated downregulation of the UPR branches
in high-grade PIN in Nkx3.1:Pten mutant mice, a mouse model of
PCa. Expression of some ER-associated molecules, such as
HERPUD1 and NDRG1, was reduced in PCa samples from patients
(Segawa et al, 2002), and GRP78 expression levels were associated
with greater risk of PCa recurrence and worse survival (Pootrakul
et al, 2006; Daneshmand et al, 2007).
PCa cells are highly secretory and are regulated by hormonal
signals, in particular androgen signaling, via the androgen receptor
(AR), which is important in the initiation and progression of PCa
(for a review, see Bluemn & Nelson, 2012). We thus postulated that
PCa cells may have developed ways to engage the ER adaptive
responses and hormonally regulate UPR to sustain normal tissue
integrity which may also support prostate tumorigenesis. Here, we
show that androgens induce a unique UPR profile in PCa cells by
activating the IRE1a branch, but coordinately inhibit PERK signal-
ing, to regulate growth and survival of PCa in vitro and in vivo.
These data may have translational implications.
Results
AR and UPR gene expression are correlated in prostate cancer
Given the role of androgens in PCa progression and the secretory
function of the prostate that would increase burden on ER, we
hypothesized that UPR signaling may be affected by AR signaling.
To assess this, we investigated the possible concordance between
AR and UPR gene expression in a gene expression data set from 190
human PCa tumors. AR expression in the PCa tumors was signifi-
cantly correlated with UPR gene expression (Supplementary Fig S1
and Supplementary Table S1). The tumors were then stratified
into three groups according to AR status, that is ARLow (n = 60),
ARmedium (n = 70), and ARhigh (n = 60), and assessed for UPR gene
expression. As shown in Fig 1A, stratified AR levels correlated with
UPR gene expression (Supplementary Table S2). The expression
profiles of prominent UPR genes, including ERN1 (IRE1), ER
degradation-enhancing alpha-mannosidase-like 1 (EDEM1), ATF6
and DNAJC3 (or 58 kDa interferon-induced protein kinase, P58IPK),
are presented separately for ease of evaluation (Fig 1B). These data
were validated using an independent patient cohort (Supplementary
Table S3), suggesting that AR and UPR gene expression are linked
in PCa.
Androgens activate the IRE1a branch of the UPR in vitro
and in vivo
We next assessed whether androgens affect UPR gene expression in
LNCaP PCa cells. IRE1a expression was significantly increased in a
time-dependent manner upon androgen administration (Fig 2A).
Consistently, the expression of the principal IRE1a target, XBP-1S,
was significantly increased in a similar manner (Fig 2B). In contrast,
there was a very marginal, but significant change in the levels of
unspliced XBP-1 expression (Supplementary Fig S2A). Furthermore,
the expression of several established XBP-1S target genes, such as
ER-localized DnaJ 4 (ERdj4), P58IPK, ribosome-associated
membrane protein 4 (RAMP4), and EDEM1, was robustly increased
in response to androgen treatment (Supplementary Fig S2B–E). We
then studied possible androgen regulation of the IRE1a branch in a
preclinical model of human PCa, CWR22. In response to androgen
withdrawal by castration, CWR22 tumors regress due to a decrease
in cell growth and an increase in apoptosis, similar to the in situ
disease (Wainstein et al, 1994). IRE1a expression significantly
decreased upon castration up to 72 h followed by an increase back
to basal levels by 120 h (Fig 2C). XBP-1S expression significantly
decreased after 72 h reaching approximately 40% of basal levels at
120 h (Fig 2D), whereas XBP-1U expression was not affected
(Fig 2E). Consistently, the IRE1a pathway was also activated at the
protein level with increases in phosphorylated IRE1a, total IRE1a
and XBP-1S levels in LNCaP cells upon androgen treatment
(Fig 2F).
Androgens differentially regulate the three canonical
UPR pathways
We then assessed possible androgen effects on the PERK pathway.
PERK activation results in eIF2a phosphorylation which inhibits
translation, thus alleviating ER stress by decreasing misfolded
protein overload. Both total and phosphorylated PERK levels were
significantly decreased in LNCaP cells upon androgen treatment
(Fig 2G). Consistently, p-eIF2a levels rapidly decreased upon andro-
gen exposure confirming inhibition of the PERK pathway (Fig 2G).
In addition to general inhibition of protein synthesis, eIF2a phos-
phorylation simultaneously promotes the translation of a subset of
UPR target proteins such as ATF4 (Holcik & Sonenberg, 2005).
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Whereas ATF4 mRNA expression was not affected (Supplementary
Fig S3A), ATF4 protein levels were increased (Fig 2F). In addition,
expression of CHOP, a downstream target of ATF4, was significantly
decreased upon androgen treatment (Supplementary Fig S3B) at the
mRNA level, but its protein levels increased in response to androgen
treatment (Fig 2G). Altogether, these data indicate that androgens
selectively activate the adaptive IRE1a arm of the UPR, while simul-
taneously inhibiting the PERK branch. Supporting this, similar data
were obtained in VCaP cells, another androgen-responsive cell line
(Supplementary Fig S4A). LNCaP cells treated with the natural
androgen dihydrotestosterone (DHT) induced a similar UPR
response as R1881 with an increase in IRE1a and a downregulation
in p-eIF2a expression (Supplementary Fig S4B), confirming that the
divergent UPR response to androgens is physiological.
To determine whether androgens may also affect the third canoni-
cal UPR pathway, we investigated the targets of the ATF6a branch.
The reagents available are at present limited to assay for the activation
of this pathway in human cells. However, as shown above (Supple-
mentary Fig S2A), the ATF6a target XBP-1U expression was only
slightly increased upon androgen treatment. Similarly, expression of
another ATF6a target gene, GRP78, was only modestly (approximately
2-fold) increased by androgens (Supplementary Fig S3C). These data
BA
Figure 1. Correlation of AR and UPR gene expression in prostate cancer cohorts.
A Possible correlation between AR- and UPR-associated gene expression was assessed in the global gene expression data available in the TCGA Prostate
Adenocarcinoma cohort (n = 190) (http://www.cbioportal.org/public-portal/index.do). Tumors were stratified according to AR status into three groups, that is ARlow
(n = 60), ARmedium (n = 70), and ARhigh (n = 60). The levels of UPR gene expression in the three groups were compared using Pearson’s correlation analysis by the
R software and presented as a heatmap. There were significant differences between the three groups (Supplementary Table S2).
B The expression profiles of some prominent UPR genes from the data in (A), including ERN1 (IRE1), EDEM1, ATF6, and DNAJC3 (P58IPK), are presented. P-values of the
different genes are given.
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suggest that androgens may activate the ATF6a pathway, but to a
significantly lesser degree compared to the IRE1a arm.
IRE1a signaling inhibits apoptosis in prostate cancer cells
One target of IRE1a is c-Jun N-terminal Kinase (JNK) (Urano
et al, 2000; Nishitoh et al, 2002). Since IRE1a-XBP-1S signaling is
generally involved in proliferative effects, whereas JNK induces
apoptosis in PCa cells (Lorenzo & Saatcioglu, 2008), we determined
androgen effects on JNK activation. UV-induced JNK activation was
significantly reduced in response to androgen stimulation (Supple-
mentary Fig S4C). These data are consistent with previous findings
showing that androgens block JNK activation in PCa cells, triggered
by UPR inducers, such as thapsigargin (e.g., Lorenzo & Saatcioglu,
2008).
We next determined whether IRE1a knockdown may have an
effect on PCa cell viability. As shown in Supplementary Fig S5A,
there was a significant increase in apoptosis in LNCaP cells upon
IRE1a knockdown which coincided with cleavage of caspase-3
(Supplementary Fig S5B). XBP-1 knockdown also increased caspase-3
cleavage, suggesting that the whole IRE1a-XBP-1 signaling is involved
in cell viability in PCa cells. Together with the results from above,
these data show that androgens activate the proliferative IRE1a
signaling and simultaneously inhibit proapoptotic JNK signaling.
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Figure 2. Androgens divergently regulate the UPR arms.
LNCaP cells were cultured and treated with R1881 for the indicated times.
A, B mRNA expression levels in LNCaP cells for the indicated genes were investigated using quantitative PCR (qPCR). Controls were treated with vehicle for 84 h and set
to 100. Data represent the mean of three independent experiments in triplicate, and bars represent SE. P-values ranged between 1.66 × 105 and 0.025, and IRE1a
expression in R1881 48 h was *P = 0.013 with respect to vehicle-treated cells using unpaired Student’s t-test.
C–E IRE1a, XBP-1S, and XBP-1U mRNA in CWR22 xenografts grown in nude mice and collected at the indicated times after castration. The value at t = 0 was set to 1.
Columns represent the mean of at least three independent tumors for each time point, and bars represent SE. P-values ranged between 5.7 × 1010 and 0.0002.
IRE1a expression at 48 h post-castration was 3.17 × 106 with respect to t = 0 using unpaired Student’s t-test.
F, G Protein expression in LNCaP cells upon treatment with R1881 for the indicated times by Western blot analysis. Data presented are representative of three
independent experiments.
Source data are available online for this figure.
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AR knockdown differentially affects UPR gene expression
We then investigated whether the androgen effects on UPR signaling
require AR. siRNA-mediated knockdown of AR in LNCaP cells
resulted in 60–70% reduction in AR levels (Fig 3A), which comple-
tely blocked R1881-induced IRE1a expression compared to cells
treated with control siRNA (Fig 3B). Similarly, AR knockdown
prevented androgen-induced XBP-1S expression (Fig 3C), whereas
XBP-1U expression was not affected (Fig 3E). In contrast, AR knock-
down increased CHOP expression (Fig 3D) without affecting ATF4
levels (Supplementary Fig S6E). Expression of other XBP-1S targets,
such as P58IPK, EDEM1, RAMP4, and ERdj4, was also significantly
decreased upon AR knockdown (Supplementary Fig S6A–D) under-
scoring the importance of AR for IRE1a signaling in PCa cells.
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Figure 3. AR knockdown differentially influences transcription of the different UPR members.
After starvation, LNCaP cells were transfected with control (CTRL) siRNA or AR siRNA. Cells were then treated with R1881 for the indicated times. Controls were treated with
vehicle for 48 h.
A Expression level of AR mRNA upon siRNA treatment for 48 h assessed by qPCR in LNCaP cells. Expression in cells transfected with CTRL siRNA was set to 1. Bars
represent SE with *P = 0.001 indicating significant difference between AR siRNA- and control siRNA-transfected cells using paired Student’s t-test.
B–E Same as in (A), but mRNA expression levels of the indicated UPR genes were determined by qPCR at indicated time points after R1881 stimulation. Expression in
cells transfected with CTRL siRNA was set to 100. Bars represent SE. P-values are shown indicating significant difference between AR siRNA- and control siRNA-
transfected cells using unpaired Student’s t-test.
F Expression of the indicated proteins under conditions indicated on the top label was determined by Western blot analysis. Representative blots for three
independent experiments are shown.
Source data are available online for this figure.
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Similar results were obtained at the protein level (Fig 3F, quantifica-
tion is shown in Supplementary Fig S6F). Taken together, these data
show that AR is required for selective androgen regulation of the
canonical UPR pathways.
Direct AR binding to UPR gene regulatory sequences
The data presented above indicated that AR may directly bind to
regulatory sites in UPR genes. To assess this, we examined a data
set from chromatin immunoprecipitation sequencing (ChIP-seq)
experiments with AR in LNCaP and VCaP cells (Massie et al, 2011)
which suggested that AR directly binds to several of the UPR-
associated genes. To validate these observations, we performed
individual ChIP experiments. AR efficiently loaded on to its classical
target (Brookes et al, 1998) in the PSA enhancer upon androgen
treatment in LNCaP cells (Fig 4A). Two sites predicted by ChIP-Seq
data for IRE1a showed approximately 6- and 8-fold enrichment of
AR binding upon androgen treatment (Fig 4A). In addition, XBP-1S
target genes RAMP4 and EDEM1 had a 2.5- to 4-fold increase in AR
binding upon androgen treatment (Fig 4A). Similar results were
obtained in VCaP cells (Fig 4B). These data show that AR directly
binds to regulatory sites in the vicinity of genes involved in the
IRE1a pathway and regulate their expression.
IRE1a or XBP-1 loss inhibits prostate cancer cell growth both
in vitro and in vivo
Since AR signaling is an established proliferative pathway in PCa
cells, we explored whether IRE1a signaling may affect PCa cell
growth. Knockdown of IRE1a or XBP-1 led to a significant decrease
in LNCaP cell proliferation (Fig 5A). Ectopic expression of XBP-1S
in IRE1a knockdown cells restored proliferation back to the level of
control cells (Fig 5B) showing that the effects of IRE1a in PCa cells
are mediated through XBP-1S. These findings support the data from
above that IRE1a pathway, through XBP-1S, increases proliferation
in PCa cells.
To further explore the nature of IRE1a signaling in PCa, we
established LNCaP cell lines stably expressing short hairpin RNAs
(shRNAs) directed against IRE1a and XBP-1 using lentiviral gene
delivery (Fig 5C and D). The IRE1a-depleted cells (LN-shIRE1) had
significantly reduced proliferation compared with control cells
(LN-shScr) (Fig 5C and Supplementary Fig S7A–C); similar results
were obtained upon XBP-1 depletion (Fig 5D) consistent with tran-
sient knockdown experiments (Fig 5A). The reduction in growth in
either cell line was rescued, at least in part, by androgen
treatment, and the rescue was almost complete for LN-shXBP-1
cells upon long-term androgen treatment (Supplementary Fig S7A
and B). The levels of AR or its responsiveness to R1881 were
essentially the same in the different cell lines (Supplementary Fig
S7D). Taken together, these data indicate that the androgen-
mediated induction of IRE1a and XBP-1S confers a survival
advantage to PCa cells. However, IRE1a depletion did not syner-
gize with the anti-androgen MDV3100 on LNCaP cell growth
inhibition, suggesting that other factors may be involved in this
process (Supplementary Fig S7E).
To check the in vivo validity of these findings, IRE1a and XBP-1
knockdown lines were used in xenograft experiments in nude mice.
Whereas all cell lines formed tumors and the control LN-Scr tumors
continued to grow throughout the experiment, LN-shIRE1 and LN-
shXBP-1 tumors essentially stopped growing at 4–5 weeks and by
8 weeks were only approximately 40% in size compared with
control tumors (Fig 5E). In agreement with this, there was a
decrease in staining of the proliferative marker PCNA in tumors
derived from LN-shIRE1 and LN-shXBP-1 cells compared to control
tumors (Fig 5F). These data show that the IRE1a/XBP-1 pathway is
essential for PCa tumor growth in vitro and in vivo.
A small molecule inhibitor of IRE1a blocks prostate
cancer growth
The data presented above showed that IRE1a signaling is critical for
PCa cell viability and growth. We therefore evaluated the possibility
that specific pharmacologic inhibition of IRE1a can interfere with
PCa growth. To that end, we used a recently identified inhibitor of
IRE1a, toyocamycin (Ri et al, 2012), and assessed its ability to
inhibit IRE1a signaling and PCa growth in vitro and in vivo. Consis-
tent with findings in other cell lines (Ri et al, 2012), toyocamycin
inhibited XBP-1 splicing in LNCaP cells confirming IRE1a inhibition
(Supplementary Fig S8A). Toyocamycin treatment inhibited LNCaP
cell growth in a dose-dependent manner (Supplementary Fig S8B).
Consistently, when LNCaP cells were grown as xenografts in nude
mice, tumor growth in mice injected with toyocamycin was signifi-
cantly slower compared to mice receiving vehicle alone (Fig 6A).
Similar results were obtained in experiments using VCaP cells
(Fig 6B). The level of spliced XBP-1 was significantly lower in
tumors treated with toyocamycin compared to control tumors,
confirming that the observed results are caused by inhibition of
IRE1a (Fig 6C). Consistent with reduced proliferation in response to
toyocamycin, PCNA expression in tumors significantly decreased
upon toyocamycin treatment (Fig 6D). Taken together, these results
show that specific pharmacologic targeting of IRE1a can be a poten-
tial therapeutic strategy for PCa.
XBP-1S expression in human prostate cancer
To evaluate the potential application of our findings to human PCa
further, we examined the expression of XBP-1S by immunohisto-
chemical analysis on human radical prostatectomy specimens (the
available antisera for IRE1a did not function in this analysis).
XBP-1S protein was expressed in the benign prostate, predominantly
in epithelial cells, and its expression was significantly increased in
PCa specimens compared to normal tissue controls (Fig 7A and B
and Supplementary Table S4). In addition, XBP-1S expression was
reduced following neoadjuvant hormone therapy and remained low
in patients that responded to therapy, indicating that XBP-1S is regu-
lated by AR in vivo and may contribute to castrate-resistant disease
(Fig 7C and D). These data show that the activity of the IRE1a arm
of the UPR is deregulated in human PCa and may have a role in
disease progression.
Discussion
Unfolded protein response has important roles both in normal devel-
opment and physiology, as well as in pathological states (Hetz et al,
2011). Our data show that androgens differentially affect the
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canonical UPR signaling arms favoring the adaptive, prosurvival path-
ways in PCa cells to promote growth and viability. As primary
survival factors in PCa, androgens generate a UPR response favoring
adaptive responses not only by activating IRE1a signaling, but also by
the inhibition of the PERK-eIF2a-axis: this would prevent the
maladaptive aspects of UPR from the cancer cell’s perspective. Consis-
tently, using chemical-genetic strategies, IRE1a and PERK signaling
were found to have opposite effects on cell viability, where IRE1a is
proliferative, whereas PERK is proapoptotic (Lin et al, 2009). This is
also consistent with previous findings where both IRE1a and CHOP
activation are directly involved in the integration of all apoptotic
pathways as a result of unresolved ER stress (Tabas & Ron, 2011). To
our knowledge, our study is the first to document divergent regulation
of the UPR by a physiological hormone and a single transcription
factor, the AR, with important pathophysiological implications.
Androgen receptor directly bound to and activated expression
of the IRE1a branch at different levels thus establishing a
“feed-forward” loop that potentially can regulate the output of the
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Figure 4. AR directly binds in the vicinity of different UPR genes.
A, B LNCaP (A) or VCaP cells (B) were cultured and treated with vehicle (C) for 48 h or R1881 for 24 and 48 h. The cells were then fixed, and ChIP assay was performed
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IRE1a arm depending on the duration/strength of the androgen
signal. These data show that the IRE1a branch of the UPR is
positively affected by direct actions of the liganded AR to restore
homeostasis and secure cell survival (Figs 2–6). We also show
that androgens coordinately inhibit JNK signaling, resulting in
proliferation and protection from apoptosis (Supplementary Fig
S4C). This is consistent with previous findings on the proliferative
and anti-apoptotic effects of androgens on PCa cells (Kaarbo et al,
2007), as well as the strong concordance between AR expression
and UPR gene expression in two large cohorts of human PCa (Fig 1;
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E Growth analysis of xenografted LNCaP tumors in nude mice. LNCaP cells expressing shRNA against IRE1a (LN-shIRE1), XBP1 (LN-shXBP-1), or control shRNA (LN-
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Supplementary Fig S1 and Supplementary Tables S1, S2 and S3). In
addition, IRE1a was shown to control cyclin A1 expression and
thereby promote cell proliferation in PCa cells (Thorpe &
Schwarze, 2010). Furthermore, the increased expression of XBP-1S
in human PCa specimens compared with normal prostate, as well
as the expression profile of XBP-1S in response to hormone ther-
apy in PCa patients (Fig 7), is consistent with a role of the IRE1a
arm of the UPR in PCa progression.
In direct contrast with the effects on the IRE1a arm, androgens
significantly inhibited the PERK pathway. Previous studies have
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indicated that PERK pathway activation may be involved in either
proliferation or apoptosis. One study reported that sustained PERK
signaling impairs cell proliferation and promotes apoptosis (Lin
et al, 2009), while others found PERK activation to be important
for cell survival and proliferation (Urano et al, 2000; Bobrovnikova-
Marjon et al, 2010). These discrepancies may be due to differences
in the cell types used, or the nature and length of the activating
stimuli. Our observations in PCa cells add another level of complex-
ity in terms of PERK signaling effects on proliferation versus apopto-
sis: Whereas PERK activation and thus eIF2a phosphorylation is
downregulated, downstream targets of this pathways, ATF4 and
CHOP, were increased at the protein level upon androgen stimula-
tion (Fig 2G). This is despite the fact that ATF4 mRNA expression is
not significantly affected, whereas CHOP mRNA expression is
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decreased by androgens (Supplementary Fig S3). One possible expla-
nation of these observations is that upon dephosphorylation of
PERK and eIF2a by androgen treatment, there is a general increase
in protein synthesis which compensates for the effects observed at
the mRNA level. The resulting net increase in ATF4 and CHOP is
significantly less than that observed with a bona fide ER stress
inducer, such as TG (Armstrong et al, 2010; Bobrovnikova-Marjon
et al, 2010; Chitnis et al, 2012). This may suggest that CHOP expres-
sion under these conditions is not high enough to trigger apoptosis
in light of the strongly activated IRE1a pathway. Alternatively, since
CHOP may act as a survival factor under certain conditions
(reviewed in Wang & Kaufman, 2014), it may improve survival in
PCa cells. Further analyses are required to uncover the details in the
regulation of the PERK pathway by androgens in PCa cells.
It is clear that the regulation of IREa expression and those of
XBP-1S target genes are through direct AR binding to these genes
and transcriptional regulation. Although nongenomic effects, for
example through crosstalk with other signaling pathways, could be
in play, the fact that AR knockdown completely inhibits androgen
regulation supports the view that the effects are direct. For the PERK
arm, the exact mechanism of repression by androgens is not clear at
present. In ChiP-Seq data sets, there is no AR binding to PERK or
eIF2a genes and thus the effects could be mediated by interaction of
AR with other signaling pathways (for a review, see Kaarbo et al,
2007). AR-mediated signaling effects could be post-transcriptional,
for example at the level of translation or protein stability. Further
studies are required to test these possibilities.
Previous work has shown that many cytotoxic conditions that are
involved in cancer development, such as hypoxia, nutrient depriva-
tion, and alterations in pH, trigger a set of pathways that include the
ER stress response (Li et al, 2011). Many parts of the ER stress
response protect cancer cells from death, and available data indicate
that ER stress has a key role in tumorigenesis (Ma & Hendershot,
2004; Tsai & Weissman, 2010). Findings in PCa to date regarding the
role of ER stress have been limited and contradictory (Segawa et al,
2002; Pootrakul et al, 2006; Daneshmand et al, 2007; Scriven et al,
2009). The data we presented here show that UPR pathways are
distinctly and coordinately regulated to promote tumor survival. This
opens up the possibility to selectively manipulate UPR branches as
therapeutic approaches in PCa. Our findings in vitro and in vivo,
including the use of a small molecule inhibitor of IRE1a to retard
PCa growth, establishes a proof-of-principle for such studies in the
future.
Materials and Methods
Cell culture
The human PCa cell line LNCaP was purchased from the American
Type Culture Collection (Rockville, MD), and the human PCa cell
line VCaP was a kind gift of Frank Smit (Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands). Cells were
routinely kept in a humidified 5% CO2 and 95% air incubator at
37°C in RPMI 1640 containing 10% fetal calf serum (FCS), 50 U/ml
penicillin, 50 lg/ml streptomycin and 2 mM L-glutamine (all
purchased from BioWhittaker-Cambrex). The hormone responsive-
ness and expression of proteins characteristic to each cell line were
tested on a regular basis. For the experiments, cells were plated in
full medium containing 10% FCS and then preincubated in either
medium containing 2% charcoal-treated (CT) FCS for 3 days or for
2 days and an additional day in medium containing 0.5% CT-FCS.
For Western blot analysis, VCaP cells were cultured in 10% CT-FCS
for 3 days before treatment, while for ChIP experiments, they were
grown in 5% CT-FCS for 2 days before the addition of hormone.
Where indicated, cells were then treated with the synthetic andro-
gen R1881 (107 M or 108 M) or dihydrotestosterone (DHT)
(100 nM) for the various time points. Both concentrations of R1881
had a similar proliferative effect on LNCaP cell growth and affected
gene expression similarly. All cell lines were routinely tested and
were negative of mycoplasma contamination.
Generation of stable knockdown cells
Lentivirus-mediated stable knockdown cells were generated as
described previously (Wang et al, 2010).
Ectopic expression of XBP-1
LNCaP cells were transfected with the indicated siRNA (5 nM) using
Lipofectamine RNAiMax reagent. One day after siRNA transfection,
the cells were transfected with either vector control or Flag-XBP-1S
(Addgene plasmid #21833) (Calfon et al, 2002). Three days after
transfection, cells were harvested for Western blot analysis or split
into 96-well plates before cell proliferation was assessed using the
CCK-8 assay.
RNA interference
Small interfering RNA (siRNA) was used to silence AR. The siRNA
duplex used for targeting human AR was (sense strand): 50- CUGG-
GAAAGUCAAGCCCAUTTdTT-30 (Dharmacon). An siRNA targeting
the luciferase gene was used as a negative control (Qiagen). 200 nM
of the respective siRNAs was used. For silencing IRE1a or XBP-1,
siRNA against IRE1a (Santa Cruz, sc-40705) or XBP-1 (Santa Cruz,
sc-38627) or Allstar Negative Control siRNA (Qiagen) was used. siRNA
was transfected into LNCaP cells using Oligofectamine or Lipofecta-
mine RNAiMAX as per the manufacturer’s instructions (Invitrogen).
Where indicated, R1881 was added 1 h prior to siRNA transfection.
Quantitative PCR
RNA extraction, cDNA synthesis, and quantitative PCR were
performed as described previously (Klokk et al, 2007). PCR primer
sequences are available upon request. A standard curve made from
serial dilutions of cDNA was used to calculate the relative amount
of the different cDNAs in each sample. The values were normalized
to the relative amount of the internal standard GAPDH. The experi-
ments were performed in triplicate and repeated thrice with consis-
tent results.
Western blot analysis
Whole-cell extracts were made as previously described (Engedal
et al, 2002), resolved by SDS–PAGE and transferred to a PVDF
membrane (Bio-Rad). The blotted membrane was blocked in 5%
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nonfat dry milk in Tris-buffered saline (TBS) containing 0.1%
Tween (TBS–Tween) for 1 h followed by incubation with primary
antibody in TBS–Tween containing 5% bovine serum albumin
(BSA) for 14–16 h at 4°C. Antibodies used were against IRE1a
(3294S), phospho-PERK (3179S), PERK (3192S) phospho-eIF2a
(9721L), eIF2a (9722S), phospho-JNK (9251L), JNK (9252), ATF4
(11815S), cleaved caspase-3 (9661L), PCNA (13110S) (Cell Signal-
ing), XBP-1 (sc-7160), CHOP (sc-7351), PSA (sc-7638), b-actin
(sc-58670), GAPDH (sc-47724), b-tubulin (sc-9104) (Santa Cruz),
a-tubulin (Sigma-Aldrich), AR (06-680) (Upstate), and phospho-IRE1a
(PA1-16927) (Thermo Scientific). The membranes were then incu-
bated with horseradish peroxidase-conjugated anti-rabbit IgG or
anti-mouse IgG (Sigma-Aldrich) secondary antibodies in 5% nonfat
dry milk dissolved in TBS–Tween for 1 h at room temperature. ECL
Western blotting analysis system was utilized for detection of the
immunoreactive bands according to the manufacturer’s instructions
(Amersham Pharmacia Biotech).
Chromatin immunoprecipitation (ChIP)
ChIP experiments were carried out according to the standard proto-
col (Upstate Biotechnology). LNCaP or VCaP cells were plated in
15-cm tissue culture plates and cultured as described above. Cells
were treated with R1881 or vehicle for 24 and 48 h followed by a
crosslinking step (1% formaldehyde at 37°C), and a quenching step
with 125 mM glycine. Chromatin was sonicated using the Bioruptor
sonicator (Diagenode) and was immunoprecipitated with antibodies
against AR (Santa Cruz, sc-816) or IgG (Vector Laboratories;
I-1000). After reversal of crosslinking, immunoprecipitated DNA, as
well as input DNA, was quantified by qPCR. Primers used are avail-
able upon request. Standard curves were created by 10-fold serial
dilutions of an input template. The data shown are representative of
at least three independent experiments.
Xenografts
Xenografting and growth of LNCaP and VCaP cells were performed as
previously described (Jin et al, 2013). All procedures on mice, includ-
ing mouse strain, animal sex, age, number of animals allowed, and
housing, were conducted according to an experimental protocol
approved by the University of Oslo Institutional Animal Care and Use
Committee. Briefly, five million cells were suspended in 50 ll
RPMI-1640 medium and mixed with 50 ll matrigel (BD Biosciences).
The mixture was then subcutaneously inoculated into male nude mice
(BALB/c Nu/Nu, 5 weeks of age) in both hind flanks. Tumor size
was measured weekly in two dimensions with calipers, and the tumor
volume V was calculated according to the formula: V =W2 × L × 0.5,
where W and L are tumor width and length, respectively. For the
treatments, the tumor-bearing mice were divided into two groups
where the mean tumor volumes were approximately equal. No blind-
ing was carried out. Mice were treated by intraperitoneal injection of
0.5 mg/kg toyocamycin (Sigma) or saline solution as vehicle twice
weekly until the end of the experiment.
Immunohistochemistry
The prostate tissue microarrays (TMAs) were previously described
(Klokk et al, 2007; Wang et al, 2010). After deparaffinization,
antigen retrieval was done by autoclaving at 121°C for 10 min in
10 mM citrate buffer (pH 6.4). The affinity-purified XBP-1S antibody
(Biolegend, #619501) was used at a dilution of 1:50 for 1 h at room
temperature. The Supersensitive Detection kit (Biogenex) was used
for antigen detection (Klokk et al, 2007). For scoring, values on a
four-point scale (negative, weak, moderate and strong) were
assigned to each immunostain. To compare XBP-1S expression
between benign and malignant tissue, Mann–Whitney test was
applied. This study was approved by the Regional Ethics Commit-
tee, REK Sør-Øst (S-07443a), and material from still living patients
was included after their written consent.
For the untreated and neoadjuvant hormone therapy (NHT)
samples, total of 108 prostate cancer specimens were obtained from
Vancouver Prostate Centre Tissue Bank. The H&E slides were
reviewed, and the desired areas were used to construct TMAs
(Beecher Instruments, MD, USA). All specimens were from radical
prostatectomies. Details of the material are presented in Supplemen-
tary Table S5. IHC was conducted by Ventana auto-stainer model
Discover XT (Ventana Medical System, Tuscan, Arizona) with
enzyme-labeled biotin streptavidin system and solvent-resistant
DAB Map kit. For scoring, values on a four-point scale were
assigned to each immunostain. Descriptively, 1 represents no
apparent staining or very weak level of staining, 2 represents a
faint or focal, questionably present stain, 3 represents a stain of
The paper explained
Problem
Androgens are important for the normal development and function of
the male reproductive system, including the prostate. Androgens regu-
late secretion, differentiation, and apoptosis of prostate cells. In addi-
tion, androgens play a central role in initiation and progression of
prostate cancer. Different physiological and pathological conditions
can lead to perturbation of endoplasmic reticulum (ER) function,
accumulation of misfolded proteins, and ER stress. In an attempt to
restore ER homeostasis, the cell mounts a response called the UPR, a
set of intracellular signaling pathways that aim to adjust the protein
folding capacity of the cell. In this paper, we address whether the
UPR may be affected by androgen signaling and if so, whether this
association is connected to prostate cancer progression.
Results
We found that androgens generated a divergent UPR response in which
the IRE1a arm was activated, whereas the PERK pathway was inhibited.
This response was mediated by the AR which bound in the vicinity of
the UPR genes. Moreover, AR and UPR gene expression were correlated
in human prostate cancer samples wherein XBP-1S was significantly
increased in cancer compared to normal prostate. In the androgen-
responsive human prostate xenograft CWR22, IRE1a and XBP-1S expres-
sion decreased upon androgen withdrawal further underscoring the
role of androgens in the induction of this pathway. Depletion of IRE1a
or its downstream target XBP-1 led to decreased cell growth in vitro
and in vivo. Furthermore, a small molecule drug targeting IRE1a
profoundly inhibited prostate cancer cell growth in vitro as well as
tumor formation in preclinical models of prostate cancer in vivo.
Impact
In summary, these results suggest that androgens induce a divergent
UPR response to promote prostate cancer growth and that targeting
IRE1a signaling may have utility as a novel therapeutic approach in
prostate cancer.
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convincing intensity in a minority of cells, and 4 represents a stain
of convincing intensity in a majority of cells. SPSS 10.0 software
was used for IHC statistical analysis. The Kruskal–Wallis test was
used for analysis of correlation between XBP-1S expression and
tumor grade.
Statistical analysis
Mean and standard deviation values were calculated using Microsoft
Excel software. The treatment effects in each experiment were
compared using Student’s two-sided t-test unless indicated other-
wise. Values of P < 0.05 were considered as significant.
Computational analysis
The expression level of AR- and UPR-associated genes (http://www.
broadinstitute.org/gsea/msigdb/geneset_page.jsp?geneSetName=
REACTOME_UNFOLDED_PROTEIN_RESPONSE) in PCa specimens
was assessed using the gene expression datasets from two indepen-
dent studies: TCGA Prostate Adenocarcinoma cohort (n = 190) and
MSKCC Prostate Adenocarcinoma cohort (n = 126) (http://www.
cbioportal.org/public-portal/index.do). The concordance of AR
expression and UPR specific gene expression was evaluated with
Pearson’s correlation analysis using the software R.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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